CMD-504

We are developing CMD-504 for the treatment of glioblastoma and triple negative breast cancer. CMD-504 is an autologous cell therapy which consists of natural killer T (NKT) cells that have been genetically modified to express a chimeric antigen receptor (CAR).

Eligible patient population

Breast cancer is still the leading cause of cancer in women, with about 1.6 million new cases1 diagnosed each year, leading to more than 500,000 deaths globally2.  The highest medical need exists in triple negative breast cancer (TNBC) lacking the three “receptors” known to fuel most breast cancers: estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2). The most successful treatments for breast cancer target these receptors but TNBC cannot be treated by targeted therapies. It is estimated that around 17%2 of all breast cancers in the US are triple negative with Europe showing higher rates of up to 30%.   CMD-504 targets a cancer antigen (undisclosed) which is overexpressed in about 70% of all triple negative breast cancers.

Glioblastoma multiforme (GBM) is an aggressive malignancy derived from brain astrocytes.  The US National Cancer Institute estimates that 22,850 adults (12,630 men and 10,280 women) were diagnosed with brain and other nervous system cancer in 2015. It also estimates that in 2015, 15,320 of these diagnoses resulted in death.  Surgery, radiation and chemotherapy are standard treatments, but the outcomes are still quite poor and better treatments are needed.

The development of CMD-504

The clinical plan for CMD-504 is currently being developed in consultation with our clinical research partners.